Skeletal lead release during bone resorption: Effect of bisphosphonate treatment in a pilot study

Environmental Health Perspectives

Volumn 110, Issue 10, 2002, Pages 1017-1023

  Gulson, Brian ^a   Mizon, Karen ^a   Smith, Howard ^a   Eisman, John ^a   Palmer, Jacqueline ^a   Korsch, Michael ^a   Donnelly, John ^a   Waite, Kay ^a  

^a MACQUARIE UNIVERSITY   (Australia)

Author keywords

Bisphonate; Blood; Bone mineral density; Bone turnover; Isotopes; Lead; NTx test

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; LEAD; LEAD 204; LEAD 206; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUSTRALIA; BLOOD SAMPLING; BONE DEMINERALIZATION; BONE LEVEL; BONE REMODELING; BONE TURNOVER; BOSNIA AND HERZEGOVINA; CLINICAL ARTICLE; COLOMBIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; ENVIRONMENTAL EXPOSURE; FEMALE; FRACTURE; HUMAN; HYPERTENSION; LEAD BLOOD LEVEL; MALE; OSTEOLYSIS; PILOT STUDY; POSTMENOPAUSE; PREDICTION; PRIORITY JOURNAL; RUSSIAN FEDERATION; SRI LANKA; URINALYSIS;

BONUS;

EID: 0036799161     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.021101017     Document Type: Article

References (45)

1. Thomas VM, Socolow RH, Fanelli JJ, Spiro TG. Effects of reducing lead in gasoline: an analysis of the international experience. Environ Sci Technol 33:3942-3948 (1999).
2. National Academy of Sciences, National Research Council. Measuring Lead Exposure in Infants, Children, Oother Sensitive Populations. Washington, DC:National Academy Press, 1993.
3. Franklin CA, Inskip MJ, Baccanale CL, Edwards CMH, Manton WI, Edwards E, O'Flaherty EJ. Use of sequentially administered stable lead isotopes to investigate changes in blood lead during pregnancy in a nonhuman primate (Macaca fascicularis). Fundam Appl Toxicol 39:109-119 (1997)
4. Inskip MJ, Franklin CA, Baccanale CL, Manton WI, O'Flaherty EJ, Edwards CMH, Blenkinsop JB, Edwards EB. Measurement of the flux of lead from bone to blood in a nonhuman primate (Macaca fascicularis) by sequential administration of stable lead isotopes. Fundam Applied Toxicol 33:235-245 (1996).
5. Gulson BL, Jameson CW, Mahaffey KR, Mizon KJ, Korsch MJ, Vimpani G. Pregnancy increases mobilization of lead from maternal skeleton. J Lab Clin Med 130:51-62 (1997).
6. Gulson BL, Mahaffey KR, Jameson CW, Mizon KJ, Korsch MJ, Cameron MA, Eisman JA. Mobilization of lead from the skeleton during the post-natal period is larger than during pregnancy. J Lab Clin Med 131:324-329 (1998).
7. Silbergeld EK, Schwartz J, Mahaffey K. Lead and osteoporosis: mobilization of lead from bone in post-menopausal women. Environ Res 47:79-94 (1988).
8. Silbergeld EK. Personal communication.
9. Symanski E, Hertz-Picciotto I. Blood lead levels in relation to menopause, smoking, and pregnancy history. Am J Epidemiol 141:1047-1058 (1995).
10. Hernandez-Avila M, Villalpando CG, Palazuelos E, Hu H, Villalpando MEG, Martinez DR. Determinants of blood lead levels across the menopausal transition. Arch Environ Health 55:355-360 (2000).
11. Hu H, Aro A, Payton M, Korrick S, Sparrow D, Weiss ST, Rotnitsky A. The relationship of bone and blood lead to hypertension. JAMA 275:1171-1176 (1996).
12. Staessen JA, Bulpitt CJ, Fagard R, Lauwerys RR, Roels H, Thijs L, Amery A. Hypertension caused by low-level lead exposure; myth or fact. J Cardiovasc Risk 1:87-97 (1994).
13. Staessen Roels H, Fagard R. Lead exposure and conventional and ambulatory blood pressure. JAMA 275:1563-1570 (1996).
14. deCastro FJ, Medley J. Lead in bone and hypertension. Matern Child Health 1:199-200 (1997).
15. Payton M, Riggs KM, Spiro A III, Weiss ST, Hu H. Relations of bone and blood lead to cognitive function: the VA normative aging study. Neurotoxicol Teratol 20:19-27 (1998).
16. Schwartz BS, Stewart WF, Todd AC, Simon D, Links JM. Different associations of blood lead, meso 2,3-dimercaptosuccinic acid (DMSA)-chelatable lead, and tibial lead levels with blood pressure in 543 former organolead manufacturing workers. Arch Environ Health 55:85-92 (2000).
17. Kim R, Rotnisky A, Sparrow D, Weiss ST, Wager C, Hu H. A longitudinal study of low-level exposure and impairment of renal function. JAMA 275:1177-1181 (1996).
18. Muldoon SB, Cauley JA, Kuler LH, Scott J, Rohay J. Lifestyle and sociodemographic factors as determinants of blood lead levels in elderly women. Am J Epidemiol 139:599-608 (1994).
19. Koss E. Lead Exposure, Inactivity Linked to Alzheimer's. Available: http://www.cnn.com/2000/HEALTH/05/04/ alzheimers.lead.reut/index.html [cited 27 June 2000].
20. Heaney RP, Yates AJ, Santora AC. Biphosphonate effects and the bone remodelling transient. J Bone Miner Res 12:1143-1151 (1997).
21. Reid DM, Hughes RA, Lann RFJM, Sacco-Gibson NA, Wenderoth DH, Adamai S, Eusebio RA, Devogelaer J-P. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res 15:1006-1013 (2000).
22. Farias P, Borja-Aburto VH, Rios C, Hertz-Picciotto I, Rojas-Lopez M, Chavez-Ayala R. Blood lead levels in pregnant women of high and low socioeconomic status in Mexico City. Environ Health Perspect 104:1070-1074 (1996).
23. Hernandez-Avila M, Gonzalez-Cossio T, Palazuelos E, Romieu I, Aro A, Fishbein E, Peterson KE, Hu H. Dietary and environmental determinants of blood and bone lead levels in lactating postpartum women living in Mexico City. Environ Health Perspect 104:1076-1082 (1996).
24. Kalwarf HJ, Specker BL, Bianchi DC, Ranz J, Ho M. The effect of calcium supplementation on bone density during lactation and after weaning. N Engl J Med 337:523-528 (1997).
25. Chestnut CH, Bell NH, Clark GS, Drinkwater BL, English SC, Johnston CC Jr, Notelovitz M, Rosen C, Cain DF, Flessland KA, et al. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med 102:29-37 (1997).
26. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437-1443 (1995).
27. Webber CE, Chettle DR, Bowins RJ, Beaumont LF, Gordon GL, Song X, Blake JM, McNutt RH. Hormone replacement therapy may reduce the return of endogenous lead from bone to the circulation. Environ Health Perspect 103:1150-1153 (1995).
28. Osteoporosis and Fractures in Men. PA-97-009. NIH Guide 25(39): (1996). Available: http://grants1.nih.gov/grants/ guide/pa-files/PA-97-009.html [cited 17 July 2002].
29. Gulson BL, Mahaffey KR, Mizon KJ, Korsch MJ, Cameron MA, Vimpani G. Contribution of tissue lead to blood lead in adult female subjects based on stable lead isotope methods. J Lab Clin Med 125:703-712 (1995).
30. Manton WI. Sources of lead in blood: Identification by stable isotopes. Arch Environ Health 32:149-159 (1977).
31. Manton WI. Total contribution of airborne lead to blood lead. Br J Ind Med 42:168-172 (1985).
32. Kim R, Landrigan C, Mossmann P, Sparrow D, Hu H. Age and secular trends in bone lead levels in middle-aged and elderly men: three-year longitudinal follow-up in the normative aging study. Am J Epidem 146:586-591 (1997).
33. Baecklund M, Pederen NL, Bjorkman L, Vahter M. Variation in blood concentrations of cadmium and lead in the elderly. Environ Res 80:222-230 (1999).
34. Rabinowitz M. Toxicokinetics of bone lead. Environ Health Perspect 91:33-37 (1991).
35. Gulson BL, Gillings BR, Jameson CW. Stable lead isotopes in teeth as indicators of past domicile - a potential new tool in forensic science. J Forensic Sci 42:787-791 (1997).
36. CDC. Preventing Lead Poisoning in Young Children: A Statement by the Centers for Disease Control-October 1991. Atlanta, GA:Centers for Disease Control, 1991.
37. Gulson BL, Mahaffey KR, Jameson CW, Mizon KJ, Patison N, Smith AM, Law AJ, Korsch MJ. Dietary lead intakes for mother/child pairs and relevance to pharmacokinetic models. Environ Health Perspect 105:1334-1342 (1997).
38. Gulson BL, Mizon KJ, Palmer JM, Korsch MJ, Taylor AJ. Calcium supplementation minimizes mobilization of lead from the maternal skeleton during pregnancy and lactation-preliminary results [Abstract]. Presented at the Society of Toxicology Annual Meeting, 25-29 March 2001, San Francisco, CA.
39. Smith DR, Osterloh JD, Flegal AR. Use of endogenous stable lead isotopes to determine the release of lead from the skeleton. Environ Health Perspect 104:60-66 (1996).
40. 203Pb in man. Environ Res 30:188-194 (1983).
41. Gulson BL, Mizon KJ, Palmer JM, Korsch MJ, Taylor AJ. Contribution of lead from calcium supplements to blood lead. Environ Health Perspect 109:283-288 (2001).
42. Heaney RP, Recker RR, Stegman MR, Moy AJ. Calcium absorption in women: relationships to calcium intake, estrogen status, and age. J Bone Miner Res 4:469-475 (1989).
43. Leggett RW. An age-specific kinetic model of lead metabolism in humans. Environ Health Perspect 101:598-616 (1993).
44. O'Flaherty EJ. Physiologically based models for bone-seeking elements IV. Kinetics of lead disposition in humans. Toxicol Appl Pharmacol 118:16-29 (1993).
45. Heaney RP. The bone-remodelling transient: implications for the interpretation of clinical studies of bone mass change. J Bone Miner Res 9:1515-1523 (1994).